Navidea Biopharmaceuticals, Inc. (NO1A.F)
- Previous Close
0.0665 - Open
0.0665 - Bid --
- Ask --
- Day's Range
0.0665 - 0.0665 - 52 Week Range
0.0320 - 0.3020 - Volume
555 - Avg. Volume
560 - Market Cap (intraday)
6.656M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4200 - Earnings Date Apr 29, 2024 - May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.50
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
www.navidea.com11
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: NO1A.F
Compare To: NO1A.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NO1A.F
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-107.05%
Return on Equity (ttm)
--
Revenue (ttm)
610
Net Income Avi to Common (ttm)
-8.81M
Diluted EPS (ttm)
-0.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
3.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.77M
Research Analysis: NO1A.F
Company Insights: NO1A.F
NO1A.F does not have Company Insights